Tidutamab
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3) . Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) [1].
Product Specifications
CAS Number
2148354-90-7
Product Name Alternative
XmAb-18087
UNSPSC
12352203
Target
CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tidutamab.html
Purity
99.96
Solubility
10 mM in DMSO
Smiles
[Tidutamab]
Molecular Weight
(150.74 kDa)
References & Citations
[1]Hyung LS, et, al. Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. Cancer Res (2017) 77 (13_Supplement) : 3633.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
SYP-H0058-01 48 Well
Human LIF(Leukemia Inhibitory Factor) ELISA Kit
Sign In for Pricing
View Details SYP-H0058-02 96 Well
Human LIF(Leukemia Inhibitory Factor) ELISA Kit
Sign In for Pricing
View Details 75-226-FL650 200 µL
Anti-Neuregulin-CRD (Cysteine-Rich Domain, Type III) Antibody FL650 Conjugate
Sign In for Pricing
View Details 